Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 2 |
| Emerging Pharmaceutical Market: India Introduction | 9 | 1 |
| GBI Research Report Guidance | 9 | 1 |
| Emerging Pharmaceutical Market: India Macroeconomic Environment | 10 | 6 |
| Demographic Analysis | 10 | 1 |
| Population Size, Growth, and Structure | 10 | 1 |
| Mortality Rate | 11 | 1 |
| Changes in Life Expectancy at Birth | 12 | 1 |
| Improved Child Survival | 13 | 1 |
| PESTLE Analysis | 14 | 1 |
| Political Factors | 14 | 1 |
| Economic Factors | 14 | 1 |
| Social Factors | 14 | 1 |
| Technological Factors | 15 | 1 |
| Legal | 15 | 1 |
| Environmental | 15 | 1 |
| Emerging Pharmaceutical Market: India Industry Performance | 16 | 14 |
| Macroeconomic Indicators | 16 | 1 |
| Population Profile | 16 | 1 |
| High Population and Economic Growth | 17 | 1 |
| Emergence of the Middle Class | 18 | 1 |
| Disease Profile | 18 | 1 |
| Shift in Disease Profile | 18 | 1 |
| Healthcare Expenditure | 19 | 1 |
| Healthcare Regulation | 20 | 1 |
| The Union Ministry of Health and Family Welfare (MoHFW) | 20 | 1 |
| Department of Health | 20 | 1 |
| Department of Family &Welfare | 20 | 1 |
| Department of AYUSH (Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homoeopathy) | 21 | 1 |
| Autonomous Institutions Conducting Research and Development | 21 | 1 |
| National Programs and Schemes | 21 | 1 |
| National Rural Health Mission (NRHM) | 21 | 1 |
| National Health Policy 2002 | 21 | 1 |
| Accreditation Schemes | 22 | 1 |
| Highlights of Budget 2010-2011 | 23 | 1 |
| Other Government Initiatives | 23 | 1 |
| Health Insurance Regulation | 24 | 1 |
| Import &Exports | 24 | 1 |
| Imports | 24 | 1 |
| Exports | 25 | 1 |
| Top 10 Destinations of Indian Products | 26 | 1 |
| Branded &Generic Drugs | 27 | 1 |
| Peak Years of Patent Expiries to Bring Revenues to Indian Pharmaceutical Companies | 27 | 1 |
| Massive Decline in Sales of Big Pharma Companies | 28 | 1 |
| Skilled Manpower | 29 | 1 |
| Emerging Pharmaceutical Market: India Pharmaceutical and Biotech Industry | 30 | 49 |
| Introduction | 30 | 1 |
| Pharmaceutical Market Size and Growth in India | 30 | 1 |
| Domestic Market Size | 31 | 1 |
| Biotech Market Size in India | 32 | 1 |
| Pharmaceutical R&D in India | 32 | 1 |
| Forces that Drive Drug Discovery in India | 33 | 1 |
| Declining R&D Productivity, Especially for Big Pharma | 33 | 1 |
| Generics Competition Pricing Pressures on Branded Prescription Products | 34 | 2 |
| Key Pharmaceutical Regulations in India | 36 | 1 |
| The Central Drugs Standard Control Organization (CDSCO) | 36 | 1 |
| State Drug Regulatory Authority (SDRA) | 37 | 1 |
| Pricing and Reimbursement in India | 38 | 1 |
| Pricing of Pharmaceutical Drugs in India | 38 | 1 |
| Reimbursements of Pharmaceutical Drugs in India | 38 | 1 |
| Private Health Insurance | 39 | 1 |
| Health Insurance Companies Landscape | 39 | 3 |
| Intellectual Property Rights in India | 42 | 1 |
| Effect of Patent Laws on Pharmaceutical Production in India | 43 | 1 |
| Key Impact of the New Patent Laws on India | 44 | 1 |
| Patent Act 2005 First Step towards Improving IP Protection | 45 | 1 |
| IPR Enforcement Rules, 2007 | 45 | 1 |
| Trademarks Bill 2007 | 46 | 1 |
| Drugs and Cosmetics Act (Amendment) 2008 | 46 | 1 |
| EIPR (Enforcers of Intellectual Property Rights) Ensuring IPR Laws Implementation in India | 47 | 1 |
| Case 1: BMS (Bristol-Myers Squibb) versus Hetero Drugs on Dasatinib | 47 | 1 |
| Case 2: Bayer versus Cipla on Nexavar | 47 | 1 |
| Case 3: Roche versus Cipla on Tarceva | 48 | 1 |
| Key Takeaways | 48 | 1 |
| Key Marketing and Distribution Channels in India | 49 | 1 |
| Mergers and Acquisitions | 50 | 1 |
| Deals by Year | 50 | 1 |
| Deals by Type | 51 | 1 |
| Deal by Value | 51 | 1 |
| Top 10 M&A Deals | 52 | 1 |
| Strides to Acquire 50% Stake in Onco Therapies and Onco Laboratories from Aspen | 53 | 1 |
| Mitsui to Acquire 5% Stake in Arch Pharmalabs | 53 | 1 |
| Biocon to Acquire Minority Stake in Biocon Biopharmaceuticals | 53 | 1 |
| UB Group Sells 10.27% Stake in Aventis Pharma to Hoechst | 53 | 1 |
| Sanofi-Aventis Acquires Majority Stake in Shantha Biotechnics | 53 | 1 |
| Daiichi Sankyo Acquires Majority Stake in Ranbaxy Laboratories | 54 | 1 |
| Arch Pharmalabs Acquires 70% Stake in Benzochem Lifesciences | 54 | 1 |
| Fresenius Kabi Acquires 90.9% Stake in Dabur Pharma | 54 | 1 |
| Ranbaxy Laboratories Acquires 25.15% Stake in Zenotech Laboratories | 54 | 1 |
| Aspen Pharmacare Acquires Stake in Onco Therapies from Strides Arcolab | 55 | 1 |
| Licensing Agreements | 55 | 1 |
| Deals by Year | 55 | 1 |
| Deals by Value | 56 | 1 |
| Key Takeaway | 56 | 1 |
| Top 10 Licensing Deals | 56 | 1 |
| Takeda Pharmaceutical Enters into Collaboration Agreement with Alnylam Pharmaceuticals | 56 | 1 |
| Algeta Signs Licensing Agreement with Bayer | 57 | 1 |
| BioInvent and ThromboGenics Enter into an Agreement with Roche | 57 | 1 |
| Sanofi-Aventis Enters into a Licensing Agreement with Merrimack Pharmaceuticals | 57 | 1 |
| Genentech Enters into Licensing Agreement with CGI Pharmaceuticals | 57 | 1 |
| Pfizer Enters into Licensing Agreement with Coley Pharmaceutical | 58 | 1 |
| Novacea Enters into Licensing Agreement with Schering-Plough for Asentar | 58 | 1 |
| Merck Enters into Licensing Agreement with Lpath | 58 | 1 |
| Merck Signs an Agreement with Idera Pharmaceuticals | 59 | 1 |
| Taiho Pharmaceutical Signs Licensing Agreement with Sanofi-Aventis | 59 | 1 |
| Key Players Foreign | 59 | 1 |
| Sanofi-Aventis | 59 | 1 |
| Company Overview | 59 | 1 |
| SWOT Analysis | 60 | 1 |
| F. Hoffmann-La Roche Ltd/Genentech, Inc. | 61 | 1 |
| Company Overview | 61 | 1 |
| SWOT Analysis | 61 | 2 |
| AstraZeneca | 63 | 1 |
| Company Overview | 63 | 1 |
| SWOT Analysis | 63 | 1 |
| GlaxoSmithKline | 64 | 1 |
| Company Overview | 64 | 1 |
| SWOT Analysis | 64 | 2 |
| Abbott Laboratories | 66 | 1 |
| Company Overview | 66 | 1 |
| SWOT Analysis | 66 | 2 |
| Key Players Domestic | 68 | 1 |
| Dr. Reddy s Lab | 68 | 1 |
| Company Overview | 68 | 1 |
| SWOT Analysis | 68 | 1 |
| Piramal Healthcare | 69 | 1 |
| Company Overview | 69 | 1 |
| SWOT Analysis | 70 | 1 |
| Biocon Limited | 71 | 1 |
| Company Overview | 71 | 1 |
| SWOT Analysis | 71 | 1 |
| Cipla Ltd. | 72 | 1 |
| Company Overview | 72 | 1 |
| SWOT Analysis | 72 | 1 |
| Ranbaxy Laboratories Limited | 73 | 1 |
| Company Overview | 73 | 1 |
| SWOT Analysis | 74 | 1 |
| Market Drivers | 75 | 1 |
| M&As Pick Up Speed | 75 | 1 |
| Established Generics Industry | 75 | 1 |
| Market Restraints | 75 | 1 |
| Weak Infrastructure | 75 | 1 |
| Financial Disparity | 75 | 1 |
| Intellectual Property (IP) Concerns | 76 | 1 |
| Unfavorable Patent Law for Bigger Companies | 76 | 1 |
| Effect of Counterfeit Medicines | 76 | 1 |
| Actions Taken By Indian Government against Counterfeit Drugs | 77 | 1 |
| Currency Fluctuation and Financial Problems will Make It Difficult to Sustain the Growth | 77 | 1 |
| Regulatory Hurdles | 78 | 1 |
| SWOT Analysis of Indian Pharmaceutical Sector | 78 | 1 |
| Emerging Pharmaceutical Market: India Service Industries CMO, CRO | 79 | 23 |
| CMO Market Size and Growth in India | 79 | 1 |
| Overview of Indian Contract Manufacturing Organization (CMO) Market | 79 | 1 |
| Key Players Domestic | 80 | 1 |
| Piramal Healthcare | 80 | 1 |
| Business Description | 80 | 1 |
| Jubilant Organosys | 80 | 1 |
| Business Description | 80 | 1 |
| BASF | 81 | 1 |
| Business Description | 81 | 1 |
| Key Players - Foreign | 81 | 1 |
| Lonza | 81 | 1 |
| Business Description | 81 | 1 |
| Evonik | 82 | 1 |
| Business Description | 82 | 1 |
| DSM | 82 | 1 |
| Business Description | 82 | 1 |
| CMO Market Drivers | 83 | 1 |
| Low-Cost Skilled Labor | 83 | 1 |
| Increase in Generics | 83 | 1 |
| Product Patent Regime | 83 | 1 |
| Vertically Integrated Business Model | 83 | 1 |
| Strategic Partnerships | 83 | 1 |
| CMO Market Restraints | 84 | 1 |
| Increasing Competition from China | 84 | 1 |
| Time-Consuming Development Periods | 84 | 1 |
| Need for Robust Execution Strategy | 84 | 1 |
| Poor Intellectual Property Protection and Regulatory Framework | 85 | 1 |
| Threat of Counterfeit Medicines Originating from India | 85 | 1 |
| Varied Compliance With cGMP Guidelines Across the Nation | 85 | 1 |
| High Effective Tax Rates | 85 | 1 |
| Clinical Research Organization (CRO) Market Size and Growth in India | 85 | 1 |
| Major CRO Locations in India | 86 | 1 |
| Clinical Trials Registered in 2009 in India | 86 | 2 |
| Key Players Foreign | 88 | 1 |
| Quintiles | 88 | 1 |
| Business Description | 88 | 1 |
| Paraxel | 88 | 1 |
| Business Description | 88 | 1 |
| Pharmaceutical Product Development (PPD) Inc. | 89 | 1 |
| Business Description | 89 | 1 |
| Key Players Domestic | 89 | 1 |
| SIRO Clinpharm Pvt Ltd | 89 | 1 |
| Business Description | 89 | 1 |
| Veeda Clinical Research Ltd | 90 | 1 |
| Business Description | 90 | 1 |
| GVK Biosciences Pvt Ltd | 91 | 1 |
| Business Description | 91 | 1 |
| Ecron Acunova | 92 | 1 |
| Business Description | 92 | 1 |
| Synchron Research Services Pvt Ltd | 93 | 1 |
| Business Description | 93 | 1 |
| CRO Market Drivers | 94 | 1 |
| High Risks and Costs Associated With Drug Development | 94 | 1 |
| Escalating Cost of Clinical Trials | 95 | 1 |
| Increase in Multinational Sites to Conduct Clinical Trials Will Drive the Clinical Trials Market in India | 96 | 1 |
| Increased Patient Availability due to Major Diseases | 97 | 1 |
| Global Increase in the Number of Clinical Trials Conducted | 97 | 1 |
| Restructuring the R&D | 98 | 1 |
| Increased Screening Rates During R&D | 99 | 1 |
| Expiring Patents Pressurize Pharmaceutical Companies to Reduce Costs | 99 | 1 |
| CRO Market Restraints | 99 | 1 |
| Lack of Training for Clinical Trial Professionals | 99 | 1 |
| Quality of Clinical Trial Data | 99 | 1 |
| ICH GCP vs. Indian GCP | 99 | 1 |
| Article 39.3 of TRIPS | 100 | 1 |
| Ethical Issues | 100 | 1 |
| Illegal and unethical Clinical Trials | 100 | 1 |
| Slow Hiring in the Government Regulatory Bodies | 100 | 1 |
| The Need for Proposed Additional Documents for Importing Drugs | 101 | 1 |
| Major CRO Acquisitions | 101 | 1 |
| Emerging Pharmaceutical Market: India Health Care IT in India | 102 | 2 |
| IT Outsourcing to India | 102 | 1 |
| Cost of Setting Up A Clinical Data Management Setup In India | 103 | 1 |
| Emerging Pharmaceutical Market: India Appendix | 104 | 5 |
| Market Definitions | 104 | 1 |
| Abbreviations | 104 | 2 |
| Research Methodology | 106 | 2 |
| Macroeconomic Environment | 106 | 1 |
| Industry Performance | 106 | 1 |
| Pharmaceutical and Biotech Industry | 107 | 1 |
| Service Industries CMO, CRO | 107 | 1 |
| Health Care IT | 107 | 1 |
| Contact Us | 107 | 1 |
| Disclaimer | 107 | 1 |
| Sources | 108 | 1 |